REPLY
27.5.2021 10:17:04 CEST | Business Wire | Press release
For the third year in a row, the Reply - Digital Experience agency and group of companies topped the revenue ranking of the Bundesverband Digitale Wirtschaft (BVDW). The achieved fee turnover of 145.8 million euros in 2020 means a growth in turnover of 5.23 percent for Reply - Digital Experience. The number of employees across Germany of the companies belonging to the agency and group of companies increased by almost 70 to 1,027 people compared to the previous year.
"We are very proud to show growth in turnover and defend our top ranking position after a thoroughly challenging financial year. Many industries had to radically reconfigure themselves in the wake of the pandemic, digitalise processes and departments and in some cases reinvent entire business models. As a full-service provider, Reply - Digital Experience was able to provide the appropriate answers to the complex questions of this time," comments Dr Thomas Hartmann, member of board of Reply AG.
Thorben Fasching, Executive Partner of Reply adds: "At Reply - Digital Experience we have highly specialised competences from all areas of digital transformation. Skillful, interdisciplinary teams whose composition is tailored to these respective needs are a decisive advantage in a topic as complex as customer experience. With our extensive know-how in technical realisation, for example, through the use of AI, Robotic Process Automation or Machine Learning, we ensure that companies are and remain truly relevant to their customers."
The Reply - Digital Experience companies unite highly competent teams of specialists, concentrating their respective competences under one roof to effectively develop solutions for global corporations such as BMW, Volkswagen, Vodafone, Beiersdorf, Miles & More, Adidas, Ritter Sport, OBI and Vorwerk.
About BVDW Internet Agency Ranking
The ranking is regarded as an industry barometer of the German internet agency landscape, has been conducted annually by the BVDW since 2001 and published together with the cooperation partners High Text iBusiness, Horizont, Werben & Verkaufen. It lists agencies whose core business is the conception, creation and technical realisation of digital solutions.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210527005370/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 202615.9.2026 12:30:00 CEST | Press release
New U.S. healthcare provider (HCP) disease education initiative, Change the Tunein TRD explores the neurobiology and care pathways to support greater recognition and understanding of treatment-resistant depression (TRD) TRD occurs when people with major depressive disorder (MDD) are failed by at least two different antidepressant treatment regimens of adequate dose, duration and adherence in the same episode Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the launch of Change the Tune in TRD, a new U.S. HCP disease education initiative, to deepen understanding and increase recognition of TRD. The campaign explores the neurobiology of this distinct form of depression and is designed to help navigate care pathways for patients and providers. Change the Tune in TRD was developed to provide evidence-based education to U.S. HCPs on the longer, more persistent episodes associated
NIQ Launches Digital Purchase GeoAudiences Across Europe15.9.2026 12:00:00 CEST | Press release
Building on NIQ's GeoPurchase capabilities, the new solution extends geographic purchase intelligence into digital-first categories across Europe NIQ (NYSE: NIQ), a leading consumer intelligence company, today announced the launch of Digital Purchase GeoAudiences across five European markets. The new solution extends NIQ’s geographic audience capabilities into digital-first categories including travel, automotive, technology, telecommunications and financial services. The launch expands NIQ’s GeoPurchase offering, which currently provides syndicated audiences across 13 international markets. Digital Purchase GeoAudiences address growing demand from advertisers for purchase-informed audience intelligence across a broader range of digital-first industries and shopping environments. By combining NIQ’s digital commerce intelligence with its GeoPurchase framework, the solution helps advertisers identify geographic areas showing stronger digital shopping activity. Marketers can use these sig
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases15.9.2026 12:00:00 CEST | Press release
Multi-program collaboration leveraging QurCan’s TERP™ polymer-lipid nanoparticle delivery platformLilly to make a strategic investment in QurCan QurCan Therapeutics (“QurCan”), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic medicines through its proprietary TERP™ (Target-Engineered Responsive Polymer) platform, today announced an exclusive research and collaboration agreement with Eli Lilly and Company (“Lilly”) for the treatment of diseases of the central nervous system (CNS) and peripheral nervous system (PNS). Lilly and QurCan will collaborate on multiple research programs focused on the development of PLNP-enabled genetic medicine therapeutics for CNS and PNS delivery. Through this collaboration, QurCan will be responsible for optimizing genetic medicine therapeutics using its TERP platform, and Lilly will be responsible for further research, clinical development, and commercialization of the selected programs. “This collaboratio
Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership15.9.2026 11:16:00 CEST | Press release
Live in six markets within twelve weeks of launch, with a 19,000-person waitlist Axo Longevity today announced the close of an oversubscribed $5M seed round to expand its preventive health membership across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910642125/en/ Axo Longevity preventive health membership The round was backed by MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital and NIAN Sports & Entertainment, alongside angel investors including Dr. Jorge Planas of Clinica Planas Barcelona and Daniel Kulle, former President of H&M and former CEO of Forever 21. Developed to help people understand what is happening inside their body before symptoms appear, Axo Longevity moved from build to live operations in just twelve weeks. The platform is expanding globally, now operating in the United Kingdom, Ireland, Spain, Germany, and the Netherlands, as well as in its
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth15.9.2026 11:00:00 CEST | Press release
Highlights: David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026. Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering. Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026. David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development. Following a thorough selection process led by the Board of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom